Search Weight Loss Topics:




Jun 10

Nexstim Plc: Amendment of the terms of stock options programs and warrants – GlobeNewswire

Exercise Programs Comments Off on Nexstim Plc: Amendment of the terms of stock options programs and warrants – GlobeNewswire

Company announcement, inside information, Helsinki, 10 June 2020 at 8:30 pm (EEST)

Nexstim Plc: Amendment of the terms of stock options programs and warrants

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (Nexstim or the Company) has completed a rights issue which ended on 25 May 2020 in Sweden and on 27 May 2020 in Finland, and the Board of Directors has today on 10 June 2020 resolved to amend the share subscription prices of the Companys stock option programs 2016B-C, 2017 and 2018A as well as the exercise prices of the outstanding warrant agreements i.e. special rights to shares.

According to the terms and conditions of the stock option programs and the warrant agreements, the share subscription prices shall be amended, so that the share subscription price of such stock option programs or warrants is comparable to the price prior to the subscription rights issue. Therefore, new share subscription prices in question shall be:

The amended terms of the option rights and warrants are available on the Company's website http://www.nexstim.com/investors/share-information/.

NEXSTIM PLC

Leena Niemist, Chair of the Board

Further information is available on the website http://www.nexstim.com or by contacting:

Leena Niemist, Chair of the Board+358 9 2727 170leena.niemisto@nexstim.com

Sisu Partners Oy (Certified Adviser) Jussi Majamaa+358 40 842 4479

About Nexstim Plc

Nexstim is a Finnish medical technology company operating in international markets. Our mission is to enable the individual and efficient diagnosis and treatment of challenging brain diseases and disorders.

Nexstim has developed a pioneering non-invasive brain stimulation technology entitled SmartFocus. SmartFocus is based on transcranial magnetic stimulation (TMS) combined with a 3D navigation system. The unique technology allows the required area of brain to be stimulated accurately and individually.

The SmartFocus TMS technology is used in NBT (Navigated Brain Therapy) equipment developed by Nexstim. Marketing and distribution of the equipment for the treatment of serious depression in the USA has been authorised by FDA. NBT equipment has been CE approved in Europe for the treatment of serious depression and chronic neuropathic pain.

Furthermore, Nexstim is marketing the Navigated Brain Stimulation (NBS) equipment, developed by it and based on SmartFocus TMS technology. Nexstims NBS system is the only FDA cleared and CE marked navigating TMS equipment for the pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden trading facilities.

For more information, please visit http://www.nexstim.com

View post:
Nexstim Plc: Amendment of the terms of stock options programs and warrants - GlobeNewswire

Related Posts

    Your Full Name

    Your Email

    Your Phone Number

    Select your age (30+ only)

    Select Your US State

    Program Choice

    Confirm over 30 years old

    Yes

    Confirm that you resident in USA

    Yes

    This is a Serious Inquiry

    Yes

    Message:



    matomo tracker